NTrans Technologies BV has been founded in 2015 as a spin-off from the Hubrecht Institute (KNAW) by Prof. Niels Geijsen (Co-inventor), and Dr. Marco de Boer. NTrans Technologies has developed a proprietary technology that enables intracellular delivery of proteins and oligonucleotides into primary cells (stem cells). Our vision is to develop this technology for both research and clinical purposes as a method which is non-toxic, easy to use and more efficient in comparison to the currently used transfection and transduction methods. Our goal is to be the leader in technologies for transduction of proteins and other bioactive molecules into primary cells. We offer licensing of the unique transduction platform with thorough technical support to optimize your transduction. WE ARE LOOKING TO OUT LICENSE OUR TECHNOLOGY TO COMMERCIAL PARTNERS AND WELCOME RESEARCH COLLABORATIONS! Please contact us at: info@ntranstechnologies.com